Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis

DMM Disease Models and Mechanisms

Volumn 8, Issue 6, 2015, Pages 603-610

  Lanoix, Jean Philippe ^a,b   Lenaerts, Anne J ^c   Nuermberger, Eric L ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSERM   (France)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

C3HeB FeJ; Heterogeneity; pH; Pyrazinamide; Tuberculosis

Indexed keywords

LINEZOLID; METRONIDAZOLE; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; SUTEZOLID; TUBERCULOSTATIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C3HEB/FE MOUSE; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; INCUBATION TIME; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIAL COUNT; BAGG ALBINO MOUSE; C3H MOUSE; DISEASE MODEL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; LUNG; MICROBIOLOGY; PATHOLOGY; PH; SURVIVAL ANALYSIS; TUBERCULOSIS;

MUS;

ANIMALS; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG RESISTANCE, BACTERIAL; HYDROGEN-ION CONCENTRATION; LUNG; MICE, INBRED BALB C; MICE, INBRED C3H; MYCOBACTERIUM TUBERCULOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84930579682     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.019513     Document Type: Article

References (35)

1. Benator, D., Bhattacharya, M., Bozeman, L., Burman, W., Cantazaro, A., Chaisson, R., Gordin, F., Horsburgh, C. R., Horton, J., Khan, A. et al. (2002). Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 9332, 528-534.
2. Braber, S., Verheijden, K. A. T., Henricks, P. A. J., Kraneveld, A. D. and Folkerts, G. (2010). A comparison of fixation methods on lung morphology in a murine model of emphysema. Am. J. Physiol. Lung Cell. Mol. Physiol. 299, L843-L851.
3. Burian, A., Erdogan, Z., Jandrisits, C. and Zeitlinger, M. (2012). Impact of pH on activity of trimethoprim, fosfomycin, amikacin, colistin and ertapenem in human urine. Pharmacology 90, 281-287.
4. Canetti, G. (1955). The tubercle bacillus in the pulmonary lesion. In The Tubercle Bacillus in the Pulmonary Lesion of Man. pp. 29-85. New York: Springer Publishing Company.
5. Chew, W. K., Segarra, I., Ambu, S. and Mak, J. W. (2012). Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis. Antimicrob. Agents Chemother. 56, 1762-1768.
6. Conte, J. E., Golden, J. A., Duncan, S., McKenna, E. and Zurlinden, E. (1999). Intrapulmonary concentrations of pyrazinamide. Antimicrob. Agents Chemother. 43, 1329-1333.
7. Dartois, V. (2014). The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat. Rev. Microbiol. 12, 159-167.
8. Davis, S. L., Nuermberger, E. L., Um, P. K., Vidal, C., Jedynak, B., Pomper, M. G., Bishai, W. R. and Jain, S. K. (2009). Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob. Agents Chemother. 53, 4879-4884.
9. Dietze, R., Hadad, D. J., McGee, B., Molino, L. P. D., Maciel, E. L. N., Peloquin, C. A., Johnson, D. F., Debanne, S. M., Eisenach, K., Boom, W. H. et al. (2008). Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 178, 1180-1185.
10. Dorman, S. E., Goldberg, S., Stout, J. E., Muzanyi, G., Johnson, J. L., Weiner, M., Bozeman, L., Heilig, C. M., Feng, P.-J., Moro, R. et al. (2012). Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J. Infect. Dis. 206, 1030-1040.
11. Driver, E. R., Ryan, G. J., Hoff, D. R., Irwin, S. M., Basaraba, R. J., Kramnik, I. and Lenaerts, A. J. (2012). Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 3181-3195.
12. th world conference on lung health of the Union, abstr S19.
13. Grosset, J. (1978). The sterilizing value of rifampicin and pyrazinamide in experimental short course chemotherapy. Bull. Int. Union Tuberc. 59, 287-297.
14. Harper, J., Skerry, C., Davis, S. L., Tasneen, R., Weir, M., Kramnik, I., Bishai, W. R., Pomper, M. G., Nuermberger, E. L. and Jain, S. K. (2012). Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J. Infect. Dis. 205, 595-602.
15. Irwin, S. M., Gruppo, V., Brooks, E., Gilliland, J., Scherman, M., Reichlen, M. J., Leistikow, R., Kramnik, I., Nuermberger, E. L., Voskuil, M. I. et al. (2014). Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob. Agents Chemother. 58, 4026-4034.
16. Irwin, S. M., Driver, E., Lyon, E., Schrupp, C., Ryan, G., Gonzalez-Juarrero, M., Basaraba, R. J., Nuermberger, E. L. and Lenaerts, A. J. (2015). Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis. Dis. Model. Mech. 8, 591-602.
17. Jindani, A., Aber, V. R., Edwards, E. A. and Mitchison, D. A. (1980). The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121, 939-949.
18. Koller, F. and Leuthardt, F. (1934). Nekrose und Autolyse Beitrag zur Kenntnis der Dystrophischen Verkalkung. Klin. Wochenschr. 13, 1527-1529.
19. Kramnik, I., Demant, P. and Bloom, B. B. (1998). Susceptibility to tuberculosis as a complex genetic trait: analysis using recombinant congenic strains of mice. Novartis Found Symp. 217, 120-137; discussion 132-127.
20. Marzo, E., Vilaplana, C., Tapia, G., Diaz, J., Garcia, V. and Cardona, P.-J. (2014). Damaging role of neutrophilic infiltration in a mouse model of progressive tuberculosis. Tuberculosis (Edinb.) 94, 55-64.
21. Merle, C. S., Fielding, K., Sow, O. B., Gninafon, M., Lo, M. B., Mthiyane, T., Odhiambo, J., Amukoye, E., Bah, B., Kassa, F. et al. (2014). A four-month gatifloxacin-containing regimen for treating tuberculosis. N. Engl. J. Med. 371, 1588-1598.
22. Mitchison, D. A. and Chang, K. C. (2009). Experimental models of tuberculosis: can we trust the mouse? Am. J. Respir. Crit. Care Med. 180, 201-202.
23. Moellering, R. C.Jr. (1983). In vitro antibacterial activity of the aminoglycoside antibiotics. Clin. Infect. Dis. 5 Suppl. 2, S212-S232.
24. Mor, N., Simon, B., Mezo, N. and Heifets, L. (1995). Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother. 39, 2073-2077.
25. Rosenthal, I. M., Zhang, M., Williams, K. N., Peloquin, C. A., Tyagi, S., Vernon, A. A., Bishai, W. R., Chaisson, R. E., Grosset, J. H. and Nuermberger, E. L. (2007). Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4, e344.
26. Rosenthal, I. M., Tasneen, R., Peloquin, C. A., Zhang, M., Almeida, D., Mdluli, K. E., Karakousis, P. C., Grosset, J. H. and Nuermberger, E. L. (2012). Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob. Agents Chemother. 56, 4331-4340.
27. Vandal, O. H., Pierini, L. M., Schnappinger, D., Nathan, C. F. and Ehrt, S. (2008). A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis. Nat. Med. 14, 849-854.
28. Via, L. E., Lin, P. L., Ray, S. M., Carrillo, J., Allen, S. S., Eum, S. Y., Taylor, K., Klein, E., Manjunatha, U., Gonzales, J. et al. (2008). Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 76, 2333-2340.
29. Wallis, R. S., Dawson, R., Friedrich, S. O., Venter, A., Paige, D., Zhu, T., Silvia, A., Gobey, J., Ellery, C., Zhang, Y. et al. (2014). Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS ONE 9, e94462.
30. Wayne, L. G. and Sramek, H. A. (1994). Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38, 2054-2058.
31. Weiss, C., Tabachnick, J. and Cohen, H. P. (1954). Mechanism of softening of tubercles. III. Hydrolysis of protein and nucleic acid during anaerobic autolysis of normal and tuberculous lung tissue in vitro. AMA Arch. Pathol. 57, 179-193.
32. Williams, K. N., Stover, C. K., Zhu, T., Tasneen, R., Tyagi, S., Grosset, J. H. and Nuermberger, E. (2009). Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53, 1314-1319.
33. Williams, K., Minkowski, A., Amoabeng, O., Peloquin, C. A., Taylor, D., Andries, K., Wallis, R. S., Mdluli, K. E. and Nuermberger, E. L. (2012). Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 56, 3114-3120.
34. Zhang, Y., Permar, S. and Sun, Z. (2002). Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51, 42-49.
35. Zhu, T., Friedrich, S. O., Diacon, A. and Wallis, R. S. (2014). Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 58, 3306-3311.